Trial · NCT02976740
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
NCT02976740, Phase 2, Unknown, The First Affiliated Hospital of Xiamen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy. Trials, record NCT02976740. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02976740
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
- NCT number
- NCT02976740
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Xiamen University
- Conditions
- Lung Cancer Metastatic
- Interventions
- SBRT, Immunological Agent, Immunological Factors
- First posted
- 2016-11-29
- Last updated
- 2016-11-29
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | abscopal effect rate | at the time point of 4 weeks after completion of the combined treatment | |
| Secondary | overall survival | 1 year after completion of the combined treatment | |
| Secondary | Incidence of Adverse events | 1 year after completion of the combined treatment | |
| Secondary | objective response rate | 4 weeks after completion of the combined treatment | |
| Secondary | Incidence of immune-related adverse events | 1 year after completion of the combined treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02976740
GET https://conductscience.org/api/trials/v1/NCT02976740/registered